The SIRT1 overexpression study revealed that overexpression of SIRT1 mitigates anti-proliferative and EMT-inhibiting abilities of the combination therapy, suggesting that the combination therapy inhibits EMT of HCC cells by way of inhibiting SIRT1. The gene discussed is SIRT1; the disease is hepatocellular carcinoma.